Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

DIASHUTTLE Raman Active, Smart Diatom Frustules as Next Generation Multimodal Theranostics for Safe and Superior Colorectal Cancer Treatment

Coordinator
Consiglio Nazionale Delle Ricerche, Italy
Runs
1 July 2023 to 31 January 2027
Status
Running
EU funding
€236k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101106200

What the project is doing

In the project's own words, from its summary on CORDIS.

Colorectal cancer accounted for 12.7% of all new cancer diagnosis and 12.4% of all deaths due to cancer in European Union in 2020. Despite the advances in therapeutics, it is the most recurrent tumors in humans and third common cause of cancer-related deaths worldwide. The current treatment options include chemotherapy, radiation and surgery that are invasive and have side-effects. Also, the 1st and 2nd generation nanocarriers used in cancer therapy consisted of mono-component systems and failed due to lack of targeting molecules, remotely controlled therapeutics window, and patient-specific individualized platforms.

The project DIASHUTTLE aims to develop a novel, next-generation, smart, multifunctional and multimodal, hybrid nanotheranostic platform consisting of biosilica extracted from living diatoms for simultaneous diagnosis, treatment, and therapy monitoring of colorectal cancer. It will combine magnetic nanoparticle core, surface deposited metallic gold nanoparticles, tumor targeting biomolecule folic acid, and natural source drug astaxanthin to facilitate different modes of therapy such as magnetically guided or ligand targeted drug delivery, magnetic hyperthermia, and photothermal therapy.

It will also concurrently enable different modes of real-time monitoring such as Raman, surface enhanced Raman spectroscopy, magnetic resonance imaging, fluorescence, and photoluminescence. It is expected that the combination of different therapies will exhibit superior synergistic anti-cancer effect over monotherapy and reduce treatment delays by offering a safe and personalized approach to overcome the limitations of conventional cancer treatment.

The proposed platform will lead to less toxicity due to the use of targeting molecule and natural materials, controlled drug release, and lower effective drug concentration. Additionally, the nutrient uptake and CO2 sequestration capability of diatoms will support circular bio-economy and self-sustainability.

Topics

Who is involved

OrganisationCityCountryRole
Consiglio Nazionale Delle RicercheRomaItalyCoordinator
Swedish Algae Factory ABGoteborgSwedenAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI